These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 18330027)

  • 21. [Lenalidomide in the treatment of transfusion dependent myelodysplastic syndromes].
    Risum M; Dufva IH
    Ugeskr Laeger; 2010 Feb; 172(6):452-5. PubMed ID: 20146910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
    Aschauer G; Greil R; Linkesch W; Nösslinger T; Stauder R; Burgstaller S; Fiegl M; Fridrik M; Girschikofsky M; Keil F; Petzer A
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e143-9. PubMed ID: 26422252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
    Garcia-Manero G
    Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lenalidomide in myelodysplastic syndrome and multiple myeloma.
    Shah SR; Tran TM
    Drugs; 2007; 67(13):1869-81. PubMed ID: 17722955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agents.
    Hellström-Lindberg E
    Hematology Am Soc Hematol Educ Program; 2005; ():161-6. PubMed ID: 16304375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide.
    Göhring G; Lange K; Hofmann W; Nielsen KV; Hellström-Lindberg E; Roy L; Morgan M; Kreipe H; Büsche G; Giagounidis A; Schlegelberger B
    Leukemia; 2012 Feb; 26(2):356-8. PubMed ID: 21799512
    [No Abstract]   [Full Text] [Related]  

  • 27. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.
    Gaballa MR; Besa EC
    Ann Hematol; 2014 May; 93(5):723-33. PubMed ID: 24627193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal sequencing of treatments for patients with myelodysplastic syndromes.
    Itzykson R; Fenaux P
    Curr Opin Hematol; 2009 Mar; 16(2):77-83. PubMed ID: 19468268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Practical considerations in the use of lenalidomide therapy for myelodysplastic syndromes.
    Kurtin S; Sokol L
    Cancer Control; 2006 Dec; 13 Suppl():26-31. PubMed ID: 17242664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
    Heise C; Carter T; Schafer P; Chopra R
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving the outlook for myelodysplastic syndrome.
    Brower V
    J Natl Cancer Inst; 2012 Aug; 104(16):1204-6. PubMed ID: 22899627
    [No Abstract]   [Full Text] [Related]  

  • 32. Risk-based management of myelodysplastic syndrome.
    Steensma DP; Tefferi A
    Oncology (Williston Park); 2007 Jan; 21(1):43-54; discussion 57-8, 62. PubMed ID: 17313156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Novel therapeutic agents for myelodysplastic syndrome].
    Ishikawa T
    Rinsho Ketsueki; 2009 Oct; 50(10):1553-9. PubMed ID: 19915366
    [No Abstract]   [Full Text] [Related]  

  • 34. Immunomodulatory drugs in the treatment of myelodysplastic syndromes.
    Ortega J; List A
    Curr Opin Oncol; 2007 Nov; 19(6):656-9. PubMed ID: 17906467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [New tools and treatments in myelodysplastic syndromes].
    Cluzeau T; Fenaux P
    Rev Med Interne; 2013 Mar; 34(3):159-67. PubMed ID: 22766158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?
    DeZern AE
    Hematology Am Soc Hematol Educ Program; 2015; 2015():308-16. PubMed ID: 26637738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes.
    Giagounidis AA
    Semin Hematol; 2012 Oct; 49(4):312-22. PubMed ID: 23079061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myelodysplastic syndromes: introduction.
    Sloand EM
    Semin Hematol; 2008 Jan; 45(1):1-2. PubMed ID: 18179962
    [No Abstract]   [Full Text] [Related]  

  • 39. Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del(5q).
    Geyer JT; Verma S; Mathew S; Wang YL; Racchumi J; Espinal-Witter R; Subramaniyam S; Knowles DM; Orazi A
    Hum Pathol; 2013 Mar; 44(3):346-56. PubMed ID: 22995330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of lenalidomide in the management of myelodysplasia with del 5q.
    Kelaidi C; Eclache V; Fenaux P
    Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.